Agoniststargeting the receptors of incretin hormones, glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide, have been well established for the treatment of type 2 diabetes mellitus. There is increasing awareness that gastroenterologists and hepatologists should be treating obesity when patients present to their clinics.
Glucagon-like peptide-1 receptoragonists(GLP-1RAs) are widely used for glycemic control or weight management in patients with type 2 diabetes mellitus or overweight/obesity. However, there are concerns regarding their association with serious gastrointestinal adverse events, although findings have been inconsistent.
As we can see from the illustration, Glp-1 Agonists With Nongastric Tribulations has many fascinating aspects to explore.
Type 2 diabetes and obesity drive significant morbidity, mortality, and health care costs in the United States. Clinicians increasingly prescribe glucagon-like peptide1(GLP1) receptoragonists(GLP1-RAs) and dualGLP1and glucose-dependent insulinotropic polypeptide receptoragoniststo treat these and other conditions. However, 40% to 70% of patients experience gastrointestinal adverse ...
Abstract Glucagon-like peptide-1 (GLP-1) receptoragonistsand the dualGLP-1- and glucose-dependent insulinotropic polypeptide receptor co-agonisttirzepatide (referred to here collectively as "GLP-1-based therapy") are incretin-based therapies being used increasingly in the management of both type 2 diabetes and obesity. They are now recognized to have beneficial effects beyond improved ...
The availability of glucagon-like peptide-1 (GLP-1) receptoragonists(RAs) such as liraglutide and semaglutide, and aGLP-1and glucose dependent insulinotropic polypeptide coagonist (tirzepatide) represents a paradigm shift in the management of both type 2 diabetes and obesity. There is now considerable attention, including in the public media, on the effect of both long-acting and short ...
